Smart patch could spot chemo side effects before they become dangerous

NCT ID NCT06657183

First seen Jun 26, 2026 · Last updated Jul 24, 2026 · Updated 2 times

Summary

This trial tests whether a wearable sensor called the Alio Smart Patch can help catch early signs of febrile neutropenia, a serious infection risk from chemotherapy. Thirty adults with certain cancers will wear the patch and a glucose monitor at home, with a remote care team watching their data 24/7. The goal is to see if this constant monitoring can spot problems sooner and improve patient safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Alio Smart Patch wearable sensor
What this could lead to
If successful, this could help doctors detect and treat dangerous side effects from cancer treatment earlier, potentially reducing hospital visits.
What could go wrong
This is a very small, early-stage study with only 30 participants, so results may not apply to all patients. The patch may be uncomfortable or unreliable for some.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Case Comprehensive Cancer Center, University Hospitals Cleveland Medical Center Seidman Cancer Center

    Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.